top of page

Indivior’s opioid-treatment study of RBP-6000 meets primary and secondary endpoints

A phase 3 clinical trial of Indivior’s RBP-6000 buprenorphine monthly depot, a new drug for the treatment of opioid use disorder, has met both primary and secondary endpoints versus placebo.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page